View of Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial

Return to Article Details Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial Download Download PDF